Pyrethrum Extract

Summary

Pyrethrum Extract (CHEMBL2108766) is an approved unknown (ATC P03AC01); indicated across 1 condition including parasitic infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: P03AC01
• Indications: 1 condition
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108766
Name	Pyrethrum Extract
Type	Unknown
Max phase	4
ATC	P03AC01

Also known as: Pyrethrins, Pyrethrum, Pyrethrum extract, PYRETHRUM EXTRACT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
parasitic infectious disease	4	MONDO:0005135	EFO:0001067

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06333054	Not specified	COMPLETED	Safety and Efficacy of a Head Lice Shampoo

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).